Author(s):
Sangita A. Kale, Kedar K. Bodkhe, Upendra C. Galgatte
Email(s):
drsangitakale@gmail.com
DOI:
10.52711/0974-360X.2026.00667 
Address:
Sangita A. Kale*, Kedar K. Bodkhe, Upendra C. Galgatte
Department of Pharmaceutics, Progressive Education Society’s Modern College of Pharmacy, Yamunanagar, Nigdi, Pune 411044, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 10,
Year - 2026
ABSTRACT:
Verapamil HCl, a calcium channel blocker with a short half-life, requires frequent dosing for effective hypertension management. To enhance therapeutic efficacy and patient compliance, a capsule combining immediate-release (IR) and extended-release (ER) pellets was developed and optimized to achieve both rapid onset and prolonged drug release. Drug layering was performed on spheres followed by protective coatings using Eudragit and ethylcellulose, with a 3² full factorial design employed to optimize polymer concentrations. The formulation was evaluated through DSC, FTIR, SEM, flow properties, friability, assay, in vitro dissolution, and stability studies. The optimized batch (F4) demonstrated biphasic release with an initial 20% release within 2 hours and a cumulative release of 96% over 24 hours, following first-order kinetics with concentration-dependent release. FTIR and DSC confirmed drug–excipient compatibility, SEM revealed intact pellet coatings, and the formulation exhibited suitable mechanical and flow properties for capsule filling. Stability under accelerated conditions was maintained for five months. These findings indicate that the developed IR-ER Verapamil HCl capsule offers improved patient compliance and therapeutic efficacy in hypertension management.
Cite this article:
Sangita A. Kale, Kedar K. Bodkhe, Upendra C. Galgatte. Formulation, Development and Evaluation of Verapamil HCl Capsule (IR and ER Coated Pellets) for the Treatment of Hypertension. Research Journal Pharmacy and Technology. 2026;19(10):4782-8. doi: 10.52711/0974-360X.2026.00667
Cite(Electronic):
Sangita A. Kale, Kedar K. Bodkhe, Upendra C. Galgatte. Formulation, Development and Evaluation of Verapamil HCl Capsule (IR and ER Coated Pellets) for the Treatment of Hypertension. Research Journal Pharmacy and Technology. 2026;19(10):4782-8. doi: 10.52711/0974-360X.2026.00667 Available on: https://rjptonline.org/AbstractView.aspx?PID=2026-19-10-43
REFERENCE:
1. Al-Makki A, DiPette D, Whelton PK, Murad MH, Mustafa RA, Acharya S, Beheiry HM, Champagne B, Connell K, Cooney MT, Ezeigwe N. Hypertension pharmacological treatment in adults: a World Health Organization guideline executive summary. Hypertension. 2022; 79(1): 293–301. http://doi.org/10.1161/HYPERTENSIONAHA.121.18192
2. World Health Organization. Global report on hypertension: the race against a silent killer. Geneva: World Health Organization; 2023 Sep 19. http://doi.org/10.56296/9789240081062
3. Salve PS, Bali N, Saini N. Design and Development of Novel Synergistic Formulation of Pravastatin and Aspirin for the Treatment of Atherosclerosis and its Evaluation. Asian Journal of Pharmacy and Technology. 2016; 6(2): 61–69. https://doi.org/10.5958/2231-5713.2016.00009.X
4. World Health Organization. Global report on hypertension: the race against a silent killer. Geneva: World Health Organization; 2023 Sep 19. http://doi.org/10.56296/9789240081062
5. Mohammad R, Bansod DW. Hypertension in India: a gender-based study of prevalence and associated risk factors. BMC Public Health. 2024 Oct 1; 24(1): 2681. https://doi.org/10.1186/s12889-024-20097-5
6. Das A, Bhandari Y, Singh A, Kishore J, Goel S. Undiagnosed hypertension and its associated factors in India: A rural-urban contrast from the National Family Health Survey (2019–21). PLoS One. 2025 May 21; 20(5): e0316782. https://doi.org/10.1371/journal.pone.0316782
7. Degtyar A, Wilder ME, Richardson LD, Souffront KT. A scoping review of asymptomatic hypertension: definitions, diagnosis, and management in the emergency department. Curr Hypertens Rep. 2025 Dec; 27(1): 1–22. https://doi.org/10.1007/s11906-025-01335-6
8. Lido P, Romanello D, Tesauro M, Bei A, Perrone MA, Palazzetti D, Noce A, Di Lullo L, Calò L, Cice G. Verapamil: prevention and treatment of cardio-renal syndromes in diabetic hypertensive patients?. Eur Rev Med Pharmacol Sci. 2022 Mar 1; 26(5): 1524–1534. https://doi.org/10.26355/eurrev_202203_28217
9. Beevers G, Lip GYH, O'Brien E. ABC of hypertension: the pathophysiology of hypertension. BMJ. 2001; 322(7291): 912–916. https://doi.org/10.1136/bmj.322.7291.912
10. Palatini P, Julius S. The role of cardiac autonomic function in hypertension and cardiovascular disease. Curr Hypertens Rep. 2009; 11(3): 199–205. https://doi.org/10.1007/s11906-009-0035-4
11. Carretero OA, Oparil S. Essential hypertension: part I: definition and etiology. Circulation. 2000; 101(3): 329–335. https://doi.org/10.1161/01.cir.101.3.329
12. Puar TH, Mok Y, Debajyoti R, Khoo J, How CH, Ng AK. Secondary hypertension in adults. Singapore Med J. 2016 May; 57(5): 228–232. https://doi.org/10.11622/smedj.2016087
13. Ruskoaho HJ, Savolainen ER. Effects of long-term verapamil treatment on blood pressure, cardiac hypertrophy, and collagen metabolism in spontaneously hypertensive rats. Cardiovasc Res. 1985 Jun 1;19(6): 355–362. https://doi.org/10.1093/cvr/19.6.355
14. McTavish D, Sorkin EM. Verapamil: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs. 1989 Jul;38(1):19–76. https://doi.org/10.2165/00003495-198938010-00003
15. U.S. Food and Drug Administration. CALAN® SR (verapamil hydrochloride) sustained-release oral caplets: prescribing information. Silver Spring (MD): FDA; 2017 [cited 2025 Jun 24]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019152s041lbl.pdf
16. Karna S, Chaturvedi S, Agrawal V, Alim M. Formulation approaches for sustained release dosage forms: a review. Asian J Pharm Clin Res. 2015 Sep 1;8(5):46-53.
17. Abdul S, Bhad ME, Chandewar AV, Jain JM, Jaiswal SB. Formulation of Diclofenac Sodium Delayed-Release Disintegrating Tablets. Research Journal of Pharmaceutical Dosage Forms and Technology. 2010;2(1):77-89.
18. Sushma R, Sowjanya B, Uma MR. A review on pellets and pelletization techniques. Pharmabiotika. 2014;1(1):178–187.
19. Dong L, Yang F, Zhu Z, Yang Y, Zhang X, Ye M, Pan W, Pan H. Preparation, characterization, and pharmacokinetics evaluation of the compound capsules of ibuprofen enteric-coated sustained-release pellets and codeine phosphate immediate-release pellets. AAPS PharmSciTech. 2018 Oct;19:3057–3066. https://doi.org/10.1208/s12249-018-1119-8
20. Manoharan K, Bhaskaran NA, Kumar L. Pellets and techniques of pelletization. Research Journal of Pharmacy and Technology. 2019; 12(12):6157–6164. https://doi.org/10.5958/0974-360X.2019.01070.9
21. Maniyar D, Kadu P, Baig MI. Critical variables affecting the layering method of pelletization. Future J Pharm Sci. 2023 Aug 14;9(1):68. https://doi.org/10.1186/s43094-023-00522-z
22. Patil LP, Ghodake CA, Pawar SP, Rane BR, Gujarathi NA. Extended release formulation: an overview. Pharma Sci Monit. 2013 Jan 1; 4(1): 1–10.
23. Basani G, Yamsani MR, Sura RS. Formulation Development and Evaluation of Multiple Unit Pellet System of Tamsulosin Hydrochloride. Research Journal of Pharmacy and Technology. 2021;14(10): 5319–5324. https://doi.org/10.52711/0974-360X.2021.00927
24. Kolhe MH, Gilhotra RM, Asane GS. Development of capsule containing immediate release tablet and extended release floating tablet for monitoring release of atenolol. Research Journal of Pharmacy and Technology. 2021; 14(4): 2216–2220. https://doi.org/10.52711/0974-360X.2021.00393
25. Tirpude RN, Puranik PK, Jaiswal SB, Shehzad S. Drug multiparticulate production and coating technology–a review. Research Journal of Pharmacy and Technology. 2011; 4(1): 1-8.
26. Patil LP, Ghodake CA, Pawar SP, Rane BR, Gujarathi NA. Extended release formulation: an overview. Pharma Sci Monit. 2013 Jan 1; 4(1):1–10.
27. Debnath S, Shashank C, Babu MN, Kumar RS. Formulation and Development of a Compression coated, matrix based, tablet of Verapamil HCl using design of experiments. Asian Journal of Pharmacy and Technology. 2017; 7(3): 117–126. https://doi.org/10.5958/2231-5713.2017.00020.4
28. Yoshida MI, Gomes EC, Soares CD, Cunha AF, Oliveira MA. Thermal analysis applied to verapamil hydrochloride characterization in pharmaceutical formulations. Molecules. 2010 Apr 8; 15(4): 2439–2452. https://doi.org/10.3390/molecules15042439
29. Bunaciu AA, Hoang VD, Aboul-Enein HY. Fourier transform infrared spectroscopy is used in drug excipients compatibility studies. Appl Spectrosc Rev. 2024 Dec 12. https://doi.org/10.1080/05704928.2024.2438747
30. Aulton ME, Taylor K, editors. Aulton's pharmaceutics: the design and manufacture of medicines. 4th ed. London: Elsevier Health Sciences; 2013.
31. Ramya D, Reddy MS. Formulation and evaluation of sustained release pellets of verapamil HCL. Saudi J Med Pharm Sci. 2022; 8(10): 536–541. https://doi.org/10.36348/sjmps.2022.v08i10.007
32. Raval MK, Ramani RV, Sheth NR. Formulation and evaluation of sustained-release enteric-coated pellets of budesonide for intestinal delivery. Int J Pharm Investig. 2013 Oct; 3(4): 203–207.
33. Maremanda VD, Maertin D, Bitar M, Pandey A. Wurster technology-assisted step-by-step engineering of multi-layered pellets (sprinkles): microscopy, micro-CT, and e-tongue-based analysis. AAPS PharmSciTech. 2024 Feb 29; 25(3): 50. https://doi.org/10.1208/s12249-024-02773-2
34. Martins JM, Farinha A. Uniformity of dosage units—comparative study of methods and specifications between Eur. Pharm. 3rd and USP 23. J Pharm Biomed Anal. 1998 Dec 1; 18(4–5): 487–495. https://doi.org/10.1016/S0731-7085(98)00269-6
35. Parmar R, Patil P, Shah C, Upadhyay U. A review article on method development and validation of Verapamil by RP-HPLC method. Int J Pharm Res Appl. 2024; 9(5): 977–988. https://doi.org/10.35629/4494-0905977988
36. Jagadale ND, Gadade DD, Heda AA, Puranik PK. Formulation development and evaluation of sustained release pellets of verapamil HCl. Int J Pharm Res Dev. 2010; 1(11): 1-7.
37. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010; 67(3): 217–223.
38. Khan A, Naqvi BS, Shoaib MH, Khan J, Yousaf RI, Irfan M, Hidayatullah K, Zafar M. Stability studies of the optimized oral metoclopramide hydrochloride tablet formulations prepared for IVIVC studies. World J Pharm Sci. 2015; 3(1): 46–52.